Vascular invasion as an independent prognostic factor in lymph node negative invasive breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5767-5772

  Rezaianzadeh, Abbas ^a   Talei, Abdolrasoul ^b   Rajaeefard, Abdereza ^a   Hasanzadeh, Jafar ^a   Tabatabai, Hamidreza ^a   Tahmasebi, Sedigheh ^b   Mousavizadeh, Ali ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Node negative; Prognostic factor; Survival; Vascular invasion

Indexed keywords

EID: 84874063913     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5767     Document Type: Article

References (39)

1. Andrulis I, Bull S, Mlackestein M, et al (1998). Neu/erbB-2 amplification identifies a poor prognosis group of women with node negative breast cancer. J Clin Oncol, 16, 1340-9.
2. Ashwini N, Budrukkar, Rajiv Sarin, et al (2008). Prognostic factors in node negative premenopausal women treated with breast conserving therapy without adjuvant systemic therapy. The Breast, 17, 263-9.
3. Bekir K, Mithat C, Chamlibel M, et al (2003). Prognostic factors affecting survival and disease free survival in lymph node negative breast carcinoma. J Sur Oncology, 83, 167-72.
4. Camp RL, Rimm EB, Rimm DL, et al (2000). A high number of tumour free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome. Cancer, 88, 108-13.
5. Carlmagno C , Perrone F, Gallo C, et al (1996). C-erbB-2 overexpression decreases the benefit of adjuant tamoxifen in early-stage breast cvancer without axillary lymph node metastases. J Clin Oncol, 14, 2702-8.
6. Carol SW, H Silberman, Shelley K, et al (2002). lymph node status combined with lymphovascular invasion creats a more powerful tool for predicting outcom in patients with invasive breast cancer. Am J Sur, 184, 337-40.
7. Carter CL, Allen C, Henson DE , et al (1989). Relation of tumor size,lymph node status, and survival in 24740 breast cancer. Cancer, 63, 181-7.
8. Clayton G, K Teo, Borg N, et al (2012). Axillary recurrence in breast cancer patients following negative sentinel lymph node biopsy. Eur J Cancer, 48, 223.
9. Collett K, BO Maehle, Skjaerven R, et al (1994). Lymph node-negative breast cancer: the prognostic role and time dependency of age, tumor diameter and mean nuclear area. Oncology, 51, 323-8.
10. Fisher B, J Dignam, Wolmark N, et al (1997). Tamoxifen and chemotherapy for lymph node-negative, estrogen receptorpositive breast cancer. J Natl Cancer Inst, 89, 1673-82.
11. Florence R, Marc D, Gaetan MacGrogan, et al (2010). Is It Useful to Detect Lymphovascular Invasion in Lymph Node-Positive Patients With Primary Operable Breast Cancer? Cancer, 116, 3093-101.
12. Fujimori M, Izuo M, Takano A, et al (1968). Prognostic value of vascular invasion in breast cancer. Gan No Rinsho, 14, 389-93.
13. Gasparini G, Gullick W, Maluta S, et al (1994). C-erbB-3 and cerbB-2 protein expression in node negative breast carcinoma-an immunocytochemical study. Eur J Cancer, 30, 16-22.
14. Goldhirsch A, Glick JH, Gelber RD, et al (2001). Meeting hights:international concensus panel on treatment of primary breast cancer. J Clin Oncol, 19, 3817-27.
15. Goldhirsch A, William CW, Richard D Gelber, et al (2003). Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clinical Oncology, 21, 3357-65.
16. Goldhrisch A, Glick JH, Gelber RD, et al (2005). Metting hightlights:international expert consensus on the primary therapy of early breast cancer. Ann Oncol, 16, 1659-583.
17. Goldhirsch A, Wood WC, Gelber RD, et al (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of Oncology, 18, 1133-44.
18. Gurleyik G, Gurleyik E, Aker F, et al (2007). Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer. Acta Chir Belg, 107, 284-7.
19. Gurleyik G, F Aker, Aktekin A, et al (2011). Tumor characteristics influencing non-sentinel lymph node involvement in clinically node negative patients with breast cancer. J Breast Cancer, 14, 124-8.
20. Kim JY, MR Ryu, Jung DC, et al (2011). The prognostic significance of the lymph node ratio in axillary lymph node positive breast cancer. J Breast Cancer, 14, 204-12.
21. Kuru B, Camlibel M, Ali Gulcelik M, et al (2003). Prognostic factors affecting survival and disease-free survival in lymph nodenegative breast carcinomas. J Surg Oncol, 83, 167-72.
22. Lauria R, Perrone F, Carlomagna C, et al (1995). The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer, 76, 1772-8.
23. Lee HS, BS Kwak, Son BH, et al (2009). Prognostic factors influence on the systemic recurrence in axillary lymph node negative breast cancer. J Korean Sur Society, 77, 238-45.
24. Mohammed RAA, Ellis IO, Lee AHS, et al (2009). Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. Histopathology, 55, 1-9.
25. Neville AM, Bettelheim R, Gelber RD, et al (1992). Factors predicting treatment responsiveness and prognosis in nodenegative breast cancer. J Clin Oncol, 10, 696-705.
26. Nimeus-Malmstrom E, A Koliadi, Ahlin, C, et al (2010). Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer, 127, 961-7.
27. Park YS, BS Kwak, Son, BH, et al (2008). Prognostic factors influencing on the distant relapse in axillary lymph node negative breast cancer in Korea. E J Supplements, 6, 184-4.
28. Pauline TT, CM FRCPC, Freddy Abnousi, et al (2005). Lymphovascular invasion is associated with reduced locoregional control and survival in women with nodenegative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg, 200, 912-21.
29. Pinder SE, Ellis IO, Galea M, et al (1994). Pathological prognostic factors in breast cancer. III. Vascular invasion, relationship with recurrence and survival in a large study with long-term follow-up. Histopathology, 24, 41-7.
30. Polednak AP (2003). Survival of lymph node-negative breast cancer patients in relation to number of lymph nodes examined. Annals of Sur, 237, 163-7.
31. Port ER, S Patil, Stempel M, et al (2010). Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size a new source of bias in morbidity assessment? Cancer, 116, 1987-91.
32. Sebastian FS, G Bayer, Klaus Aumayr, et al (2004). prognostic value of lymphoangiogenesis and lymphovascular invasion in invasive breast cancer. Annals of Sur, 20, 306-13.
33. Song YJ, SH Shin, Cho JS, et al (2011). The role of lymphovascular invasion as a prognostic factor in patients with lymph nodepositive operable invasive breast cancer. J Breast Cancer, 14, 198-203.
34. Teel P (1964). Vascular invasion as a prognostic factor in breast carcinoma. Surg Gynecol Obstet, 118, 1006-8.
35. Voogd AC, NM, Peterse JL, et al (2001). Differences in risk factors for local and distant recurrence after breastconserving therapy or mastectomy for stage I and II breast cancer, pooled results of two large European randomized trials. J Clin Oncol, 19, 1688-97.
36. Woo CS, Silberman H, et al (2002). Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer. Am J Surg Pathol, 184, 337-40.
37. Young J, Shin JS, Cho MH, et al (2011). The role of lymphovascular invasion as a prognostic factor in patients with lymph node positive operable invasive breast cancer. J Breast Cancer, 14, 6.
38. Yu JB, LD Wilson, Dasgupta T, et al (2008). Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy - analysis of the NCI surveillance, epidemiology and end results database. Cancer, 113, 38-47.
39. Yuan J, Hennessy C, Givan A, et al (1992). predicting outcom for patients with node negative breast cancer,a comparative study of the value of flow cytometry and cell image analysis for determination of DNA ploidy. Br J Cancer, 65, 461-5.